The impact of HIV-1 subtype on the clinical response on HAART.
Highly active antiretroviral therapy (HAART) has led to a reduction in HIV-related mortality and morbidity. Most patients who have benefited from HAART are infected with HIV-1 subtype B, which predominates in Western Europe, the USA and the rest of the industrialised world. However, most HIV-infecte...
Main Author: | Frater, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2002
|
Similar Items
-
CMV retinitis in an HIV patient with clinical and
immunological failure on HAART
by: Dipankar Chakraborty,, et al.
Published: (2015) -
The impact of HIV on maternal morbidity in the Pre-HAART era in Uganda.
by: Nuwagaba-Biribonwoha, H, et al.
Published: (2012) -
Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.
by: Touloumi, G, et al.
Published: (2008) -
Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
by: Porter, K, et al.
Published: (2003) -
HIV/HCV coinfection, HAART, and liver-related mortality.
by: Sabin, C, et al.
Published: (2004)